| Market Capitalization (Millions $) |
1,236 |
| Shares
Outstanding (Millions) |
100 |
| Employees |
35 |
| Revenues (TTM) (Millions $) |
89 |
| Net Income (TTM) (Millions $) |
8 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
1 |
Ars Pharmaceuticals Inc
Ars Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that specializes in developing and commercializing novel therapies for various conditions in the areas of pulmonary and life-threatening diseases. The company was founded in 2009 and has its headquarters located in Waltham, Massachusetts.
Ars Pharmaceuticals Inc. is dedicated to developing innovative solutions that provide significant benefits to patients suffering from serious respiratory and related illnesses. Its primary focus is on developing inhaled nitric oxide (iNO) therapies, which are aimed at treating specific respiratory diseases such as pulmonary hypertension, ventilator-associated pneumonia, and acute respiratory distress syndrome (ARDS).
The company's lead product candidate, AP-002, is a Phase 2b/3 clinical stage inhaled nitric oxide product designed to improve oxygenation, decrease pulmonary artery pressure, and decrease right ventricular hypertrophy in patients with pulmonary hypertension. AP-002 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), which highlights the significant benefits that it could provide to patients with unmet medical needs.
In addition to its work on inhaled nitric oxide therapies, Ars Pharmaceuticals Inc. is also developing other novel products for the treatment of respiratory conditions. The company's proprietary platform technology, known as Amplivant, is used to generate targeted, nontoxic peptides that bind to specific cells and inhibit harmful inflammatory pathways. Amplivant has the potential to treat inflammation-driven diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.
Ars Pharmaceuticals Inc. is backed by a group of experienced investors, including OrbiMed Advisors, RA Capital Management, and Polaris Partners. The company has formed strategic partnerships with leading academic institutions, such as the University of Massachusetts Medical School and Duke University, to advance its research and development programs.
Overall, Ars Pharmaceuticals Inc. is a biopharmaceutical company with a clear focus on developing innovative therapies to address unmet medical needs in the areas of pulmonary and life-threatening diseases. Its commitment to its mission, along with its novel technologies and strategic partnerships, make it an exciting player in the biopharmaceutical industry.
Company Address: 11682 El Camino Real San Diego 92130 CA
Company Phone Number: 771-9307 Stock Exchange / Ticker: NASDAQ SPRY
|
11.94% 